Global Hedgehog Pathway Inhibitors Market, By Drug (Daurismo, Erivedge, Odomzo, Other), Application (Application (Basal Cell Carcinoma (BCC), Acute Lymphoblastic Leukemia (AML), Others), Dosage (Injection, Capsule, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029.
Market Analysis and Size
In recent years, the hedgehog pathway inhibitors? market is anticipated to grow rapidly during the forecast period. As per the American Cancer Society (ACS), 5.4 million people around the world are diagnosed with squamous and basal cell skin cancer each year, with 3.3 million people developing squamous cell skin cancer and over 80% of the population developing basal cell carcinoma. Increasing cases of cancer is estimated to influence the market's expansion over the forecast period. Hedgehog pathway inhibitors are preferred over conventional cancer treatments due to the growing demand for painless treatment. All these factors lead to the high demand of hedgehog pathway inhibitors in the healthcare sector.
Data Bridge Market Research analyses that the hedgehog pathway inhibitors? market was valued at USD 531.39 million in 2021 and is expected to reach USD 840.58 million by 2029, registering a CAGR of 5.90% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Hedgehog pathway inhibitors are small molecules that belong to a new family of therapeutic drugs that primarily target proteins involved in the hedgehog pathway's regulation. These proteins are a family of proteins that control cell differentiation and are involved in organogenesis, which has been shown to enhance stem cell proliferation in adults. Incorrect activation of the hedgehog signaling pathways can lead to the progression of cancers such as lung, prostate, pancreas, breast, brain, skin, and others.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug (Daurismo, Erivedge, Odomzo, Other), Application (Application (Basal Cell Carcinoma (BCC), Acute Lymphoblastic Leukemia (AML), Others), Dosage (Injection, Capsule, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Inhibitor Therapeutics, Inc. (US), MAX BioPharma (US), Mayne Pharma Group Limited (Australia), PellePharm Inc. (US), Novartis AG (Switzerland), Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Sanofi (France), Sun Pharmaceutical Industries Ltd. (India), Pfizer Inc. (US)
|
|
Market Opportunities
|
|
Hedgehog Pathway Inhibitors? Market Dynamics
Drivers
- Increasing prevalence of basal cell carcinoma and acute myeloid leukaemia
The rising prevalence of basal cell carcinoma and acute myeloid leukaemia is anticipated to influence the hedgehog pathway inhibitors? market's growth. Chronic infections, a history of skin cancer, exposure to specific chemicals, skin inflammations, smoking, and UV exposure are all risk factors for basal cell carcinoma and acute myeloid leukaemia. Basal cell carcinoma and acute myeloid leukaemia are more common as a result of these risk factors. Consequently, the hedgehog pathway inhibitors market is expected to rise throughout the forecast period.
- Increasing investment for healthcare infrastructure
Another significant factor influencing the growth rate of hedgehog pathway inhibitors? market is the rising healthcare expenditure which helps in improving its infrastructure.
Furthermore, rising initiatives by public and private organizations to spread awareness will expand the hedgehog pathway inhibitors? market. Additionally, high disposable income and sedentary lifestyle of people will result in the expansion of hedgehog pathway inhibitors? market. Along with this, rising geriatric population and favourable reimbursement policies will enhance the growth rate of the market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the hedgehog pathway inhibitors? market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.
Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the hedgehog pathway inhibitors? market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with the drug development and distribution? will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the hedgehog pathway inhibitors? market. Additionally, side effects of hedgehog pathway inhibitors? will act as market restrain and further impede the growth rate of market during the forecast period of 2022-2029.
This hedgehog pathway inhibitors? market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hedgehog pathway inhibitors? market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Hedgehog pathway inhibitors? market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
COVID-19 Impact on Hedgehog Pathway Inhibitors? Market
Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. This can be ascribed to severe disruptions in their respective manufacturing and supply-chain operations therefore as consequence of multiple precautionary lockdowns and other limitations imposed by governments all over the world. The hedgehog pathway inhibitors market is no exception. Furthermore, consumer preferences has decreased as people are now much more concentrated on removing non-essential expenses from their budgets as the wider economic situation of most people has been adversely impacted by this outbreak. Over the forecast period, the aforementioned factors are likely to have a negative impact on the hedgehog pathway inhibitors market's revenue trajectory.
Global Hedgehog Pathway Inhibitors Market Scope
The hedgehog pathway inhibitors? market is segmented on the basis of drug, application, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug
- Daurismo
- Erivedge
- Odomzo
- Other
Application
- Basal Cell Carcinoma (BCC)
- Acute Lymphoblastic Leukemia (AML)
- Others
Dosage
- Injection
- Capsule
- Others
Route of Administration
- Oral
- Parenteral
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Hedgehog Pathway Inhibitors Market Regional Analysis/Insights
The Hedgehog pathway inhibitors? market is analysed and market size insights and trends are provided by country, drug, application, dosage, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Hedgehog pathway inhibitors? market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the hedgehog pathway inhibitors? market because of the rising prevalence of basal cell carcinoma and acute myeloid leukaemia in this region. Additionally, growing presence of major key players will further propel the market’s growth rate in this region.
Asia-Pacific are expected to grow during the forecast period due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Hedgehog Pathway Inhibitors Market Share Analysis
The Hedgehog pathway inhibitors? market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hedgehog pathway inhibitors? market.
Some of the major players operating in the hedgehog pathway inhibitors? market are:
- Pfizer Inc. (US)
- Novartis AG (Switzerland)
- Abbott (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Sanofi (France)
- Sun Pharmaceutical Industries Ltd. (India)
- Inhibitor Therapeutics, Inc. (US)
- MAX BioPharma (US)
- Mayne Pharma Group Limited (Australia)
- PellePharm Inc. (US)
SKU-